Takeshi Numata
Overview
Explore the profile of Takeshi Numata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Numata T, Nakamura R, Shiozawa T, Watanabe H, Okauchi S, Ogara G, et al.
Cancer Diagn Progn
. 2025 Jan;
5(1):105-114.
PMID: 39758245
Background/aim: Atezolizumab, one of the anti-PD-L1 antibodies, targets PD-L1 expressed on cancer cells and antigen-presenting cells. This immune checkpoint inhibitor is now commonly used in combination with chemotherapy. The objectives...
2.
Hatori T, Numata T, Shiozawa T, Taguchi M, Sakurai H, Tamura T, et al.
Curr Oncol
. 2024 Nov;
31(11):6502-6511.
PMID: 39590113
Background: This study aimed to investigate prognostic factors for predicting the survival of patients with extensive-disease-stage small-cell lung cancer treated with chemoimmunotherapy. Methods: Patients were classified according to overall survival...
3.
Maezawa Y, Taguchi M, Kawakami T, Inui T, Okauchi S, Numata T, et al.
Tuberk Toraks
. 2024 Jun;
72(2):107-113.
PMID: 38869202
Introduction: In addition to the two common epidermal growth factor receptor (EGFR) mutations, there are many uncommon mutations. Due to the high number of uncommon types, as well as the...
4.
Ano S, Kikuchi N, Okauchi S, Numata T, Nakamura R, Shiozawa T, et al.
Anticancer Res
. 2024 May;
44(6):2725-2730.
PMID: 38821613
Background/aim: Atezolizumab, an anti-PD-L1 antibody, has been increasingly administered in combination with chemotherapy to patients with small cell lung cancer (SCLC). This study aimed to determine how patients with extensive...
5.
Maezawa Y, Taguchi M, Kawakami T, Inui T, Okauchi S, Numata T, et al.
Anticancer Res
. 2024 Mar;
44(4):1751-1757.
PMID: 38537995
Background/aim: The median age of subjects in many clinical trials of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor conducted to date has been approximately 60 years. However, it is not...
6.
Kurihara S, Nakamura R, Yoneyama S, Takase S, Hatori T, Yamagishi T, et al.
Anticancer Res
. 2024 Feb;
44(2):767-779.
PMID: 38307568
Background/aim: The association between resected non-small cell lung cancer (NSCLC) and long-term outcomes of muscle mass depletion and muscle weakness has also not been well documented. This study evaluated whether...
7.
Tamura T, Numata T, Yanai H, Nakamura R, Shiozawa T, Watanabe H, et al.
Anticancer Res
. 2023 Sep;
43(10):4583-4591.
PMID: 37772562
Background/aim: Atezolizumab, an anti-programed death-ligand 1 monoclonal antibody, targets programed death-ligand 1 expressed on cancer cells and antigen-presenting cells and is now commonly used in combination with chemotherapy. We conducted...
8.
Okauchi S, Ohara G, Shiozawa T, Watanabe H, Numata T, Nakamura R, et al.
In Vivo
. 2023 Aug;
37(5):2203-2209.
PMID: 37652502
Background/aim: Atezolizumab is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1) expressed on cancer cells derived from various organs and antigen-presenting cells and is currently commonly used in combination...
9.
Arai N, Nakajima M, Matsuyama M, Matsumura S, Yazaki K, Sakai C, et al.
Am J Respir Cell Mol Biol
. 2023 Aug;
69(2):242-246.
PMID: 37526393
No abstract available.
10.
Nakamura R, Yoneyama S, Tobita R, Kurihara S, Hatori T, Numata T, et al.
Anticancer Res
. 2022 May;
42(6):3159-3168.
PMID: 35641288
Background/aim: Preoperative depletion of psoas muscle mass index (PMI) in lung cancer patients is an unfavorable prognostic factor. The relationship between post-surgical changes in PMI and survival is not clear....